Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas

Endocrine-Related Cancer

Volumn 13, Issue 1, 2006, Pages 69-78

  De Sá, Sandra Valéria ^a   Corrêa Giannella, Maria Lúcia ^a   Machado, Márcio Carlos ^a   De Souza, Jean Jorge S ^a   Pereira, Maria Adelaide Albergaria ^a   Patzina, Rosely Antunes ^a   Siqueira, Sheila Aparecida Coelho ^a   Machado, Marcel Cerqueira César ^a   Giannella Neto, Daniel ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INSULIN; MESSENGER RNA; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ADOLESCENT; ADULT; AGED; ARTICLE; CELL COUNT; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE DURATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INSULINOMA; LIVER METASTASIS; MALE; MITOSIS INDEX; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

ADENOMA, ISLET CELL; ADOLESCENT; ADULT; AGED; CELL PROLIFERATION; FEMALE; HUMANS; INSULINOMA; LIVER NEOPLASMS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PITUITARY HORMONES; PITUITARY NEOPLASMS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 33645971621     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00962     Document Type: Article

References (28)

1. Bertherat J, Tenenbaum F, Perlemoine K, Videau C, Alberini JL, Richard B, Dousset B, Bertagna X & Epelbaum J 2003 Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. Journal of Clinical Endocrinology and Metabolism 88 5353-5360.
2. Bruno JF, Xu Y & Berelowitz M 1994 Somatostatin regulates somatostatin receptor subtype mRNA expression in GH3 cells. Biochemical and Biophysical Research Communications 202 1738-1743.
3. Bruns C, Lewis I, Briner U, Meno-Tetang G & Weckbecker G 2002 SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. European Journal of Endocrinology 146 707-716.
4. Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, Kalthoff H, Lluis F, Vaysse N & Susini C 1996 Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Research 56 1823-1827.
5. Cordelier P, Esteve JP, Bousquet C, Delesque N, O'Carroll AM, Schally AV, Vaysse N, Susini C & Buscail L 1997 Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. PNAS 94 9343-9348.
6. Delesque N, Buscail L, Esteve JP, Saint-Laurent N, Muller C, Weckbecker G, Bruns C, Vaysse N & Susini C 1997 sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Research 57 956-962.
7. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G & Fabiani L. 2001 The clinical management of neuroendocrine tumours with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy. Annals of Oncology 12 S105-S109.
8. Hallin M & Jurěková J 1999 Optimal tests for autoregressive models based on autoregression rank scores. Annals of Statistics 27 1385-1414.
9. De Herder WW, Hofland LJ, van der Lely AJ & Lamberts SW 2003 Somatostatin receptors in gastroentero-pancreatic neuroendocrine tumours. Endocrine-Related Cancer 10 451-458.
10. Hukovic N, Panel R, Kumar U & Patel YC 1996 Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR 1-5): subtype selective internalization or upregulation. Endocrinology 137 4046-4049.
11. Jais P, Terris B, Ruszniewsk P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M & Lewin MJ 1997 Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. European Journal of Clinical Investigation 27 639-644.
12. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S & Seino Y 1994 Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. Journal of Clinical Investigation 93 1321-1325.
13. Komminoth P, Perren A, Oberg K, Rindi G, Heitz PU & Kloppel 2004 Insulinoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C, eds. World Heath Organization Classification of Tumour. Pathology and Genetics of Tumours of Endocrine Organs, pp 183-186. Eds IARC Press, Lyon.
14. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y & Arnold R 2002 Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 50 52-60.
15. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC & Patel YC 1999 Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 48 77-85.
16. Lamberts SW, van der Lely AJ & Hofland LJ 2002 New somatostatin analogs: will they fulfil old promises? European Journal of Endocrinology 146 701-705.
17. Papotti M, Bongiovann M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL & Bussolati G 2002 Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors: A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Archiv-An International Journal of Pathology 440 461-475.
18. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E & Patel YC 2002 Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. PNAS 99 3294-3299.
19. Patel YC 1999 Somatostatin and its receptor family. Frontiers in Neuroendocrinology 20 157-198.
20. Pfaffl MW 2001 A new mathematical model for relative quantification in real time RT-PCR. Nucleic Acids Research. 29 2002-2007.
21. Raggi CC, Calabrò A, Renzi D, Briganti V, Cianchi F, Messerini L, et al. 2002 Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clinical Cancer Research 8 419-427.
22. Rochaix P, Delesque N, Esteve JP, Saint-Laurent N, Voight JJ, Vaysse N, Susini C & Buscail L 1999 Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Human Gene Therapy 10 995-1008.
23. Rozen S & Skaletsky HJ 2000 Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols, pp 365-386. Eds S Krawetz & S Misener. Totowa: Humana Press.
24. Service FJ, McMahou MM, O'Brian PC, Ballrad DJ 1991 Functioning insulinoma-incidence recurrence and long term survival of patients: a 60 year study. Mayo Clinic Proceedings 66 711-719.
25. Sestini R, Orlando C, Peri A, Tricarico C, Pazzagli M, Serio M, Pagani A, Bussolati G, Granchi S & Maggi M 1996 Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clinical Cancer Research 2 1757-1765.
26. Sharma K, Patel YC & Srikant CB 1999 C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest. Molecular Endocrinology 13 82-90.
27. Soga J & Yakuwa Y 1998 Glucagonomas/diabetico-dermatogenic syndrome (DDS): a statistical evaluation of 407 reported cases. Journal of hepatobiliary-pancreatic surgery 5 312-319.
28. Solcia E, Capella C, Klöppel G 1997 Tumor of the pancreas. In: AFIP Atlas of Tumor Pathology, 3 edn, pp 120-144. Eds Armed Forces Institute of Pathology. Washington DC.